Get the Stockscreener App
2.22
0.91%
0.02
Pre-market:
2.22
Senti Biosciences Inc stock is traded at $2.22, with a volume of 96,775.
It is up +0.91% in the last 24 hours and up +22.65% over the past month.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.
See More
Previous Close:
$2.20
Open:
$2.23
24h Volume:
96,775
Relative Volume:
0.56
Market Cap:
$58.37M
Revenue:
$1.79M
Net Income/Loss:
$-70.90M
P/E Ratio:
-0.1429
EPS:
-15.54
Net Cash Flow:
$-34.95M
1W Performance:
+5.21%
1M Performance:
+22.65%
6M Performance:
-34.51%
1Y Performance:
-66.41%
1-Day Range:
$2.10
$2.23
1-Week Range:
$2.0311
$2.25
52-Week Range:
$1.26
$7.10
Senti Biosciences Inc Stock (SNTI) Company Profile
Name
Senti Biosciences Inc
Sector
Industry
Phone
(650) 239-2030
Address
2 CORPORATE DRIVE, FIRST FLOOR, SOUTH SAN FRANCISCO
Compare SNTI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SNTI
Senti Biosciences Inc
|
2.22 | 57.84M | 1.79M | -70.90M | -34.95M | -15.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Senti Biosciences Inc Stock (SNTI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-14-25 | Initiated | H.C. Wainwright | Buy |
| Jun-06-25 | Initiated | Laidlaw | Buy |
| Oct-07-22 | Initiated | Morgan Stanley | Equal-Weight |
Senti Biosciences Inc Stock (SNTI) Latest News
Acute Myeloid Leukemia Clinical Trial Pipeline Appears Robust With 100+ Key Pharma Companies Actively Working in the Domain | DelveInsight - GlobeNewswire Inc.
Senti Biosciences, Inc. to Host Conference Call and Webcast to Discuss SENTI-202 Clinical Data Being Presented At the American Society of Hematology Annual Meeting 2025 - marketscreener.com
Senti Biosciences, Inc. to Host Conference Call on Updated Clinical Results for SENTI-202 Prior to ASH Annual Meeting - Quiver Quantitative
Senti Bio (Nasdaq: SNTI) to host Dec. 9 webcast on updated SENTI-202 data from ASH 2025 - Stock Titan
How Senti Biosciences Inc. stock reacts to oil pricesJuly 2025 Price Swings & Capital Efficiency Focused Strategies - Newser
Senti Bio Reports Second Quarter 2025 Financial Results and Confirms Next Data Milestone for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML) Expected Q4 2025 - ADVFN
Form 8-KCurrent report - ADVFN
Check Out Senti Biosciences Inc (SNTI)’s Trade Data Rather Than the Analysts’ Views - Setenews
Senti Biosciences, Inc. (NASDAQ:SNTI) Receives $8.75 Consensus PT from Analysts - Defense World
Leerink Partners Initiates Coverage on Senti Biosciences (NASDAQ:SNTI) - Defense World
SNTI Stock Skyrockets on Initial Data From Phase I Cancer Study - MSN
Leerink Partners initiates coverage on Senti Biosciences stock with Outperform rating - Investing.com Australia
Leerink Partners Initiates Coverage of Senti Biosciences (SNTI) with Outperform Recommendation - Nasdaq
Leerink Partners initiates coverage on Senti Biosciences stock with Outperform rating By Investing.com - Investing.com South Africa
SNTI Stock Rating Update: Leerink Partners Initiates Coverage | - GuruFocus
Why Senti Biosciences Inc. stock is a must watch in 20252025 Breakouts & Breakdowns & Free Long-Term Investment Growth Plans - newser.com
Is Senti Biosciences Inc. stock vulnerable to regulatory risksJuly 2025 Closing Moves & Weekly High Return Forecasts - newser.com
Why Senti Biosciences Inc. stock could benefit from AI revolutionWeekly Gains Summary & Technical Entry and Exit Tips - newser.com
Is Senti Biosciences Inc. trending in predictive chart modelsQuarterly Market Summary & Expert Approved Momentum Ideas - newser.com
Combining machine learning predictions for Senti Biosciences Inc.Quarterly Profit Review & Weekly Breakout Stock Alerts - newser.com
How Senti Biosciences Inc. stock benefits from global expansionEarnings Risk Summary & Growth Focused Stock Reports - newser.com
Building trade automation scripts for Senti Biosciences Inc.2025 Volume Leaders & Weekly Momentum Picks - newser.com
Will Senti Biosciences Inc. stock recover faster than peersEarnings Recap Report & Technical Analysis for Trade Confirmation - newser.com
Is Senti Biosciences Inc. forming a reversal patternJuly 2025 Pullbacks & Daily Market Momentum Tracking - newser.com
Will a bounce in Senti Biosciences Inc. offer an exitEarnings Risk Report & Risk Managed Investment Entry Signals - newser.com
Bicara Therapeutics (NASDAQ:BCAX) versus Senti Biosciences (NASDAQ:SNTI) Head to Head Analysis - Defense World
Senti Biosciences Inc Stock (SNTI) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.10%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):